摘要
以我国新型冠状病毒肺炎诊疗方案(试行第七版)推荐的抗病毒治疗的药物为基础,本文对临床上用于治疗抗新型冠状病毒肺炎(COVID-19)的药物包括瑞德西韦、氯喹和羟氯喹、洛匹那韦/利托那韦、法匹拉韦进行了药物代谢和药动学性质的综述,同时对作者实验室的研究成果包括阿比朵尔、黄芩苷和连花清瘟胶囊主要成分连翘苷的代谢和药动学进行了回顾,以期为治疗COVID-19药物的药效评价和合理用药提供参考。
Based on Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment(7 thedition),the metabolism and pharmacokinetics of drugs used in clinical treatment of COVID-19 were reviewed.The antiviral drugs include remdesivir,chloroquine/hydroxychloroquine,lopinavir/ritonavir,favipiravir,arbidol,baicalin,baicalein and forsythin.Among them,the metabolism and pharmacokinetics of arbidol,baicalin and forsythin are the research results of the author’s laboratory.This article aims to provide reference for the efficacy evaluation and rational drug use of COVID-19.
作者
潘露露
钟大放
PAN Lu-lu;ZHONG Da-fang(Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China)
出处
《药学学报》
CAS
CSCD
北大核心
2020年第11期2570-2579,共10页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81521005)。
